YS Biopharma Future Growth
Future criteria checks 5/6
YS Biopharma is forecast to grow earnings and revenue by 58.3% and 26.9% per annum respectively while EPS is expected to grow by 58.3% per annum.
Key information
58.3%
Earnings growth rate
58.3%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 26.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 1,803 | 432 | N/A | N/A | 1 |
3/31/2026 | 1,387 | 118 | N/A | N/A | 2 |
3/31/2025 | 827 | -122 | N/A | N/A | 2 |
3/31/2024 | 596 | -297 | N/A | N/A | 1 |
12/31/2023 | 544 | -334 | N/A | N/A | N/A |
9/30/2023 | 561 | -309 | -283 | -221 | N/A |
6/30/2023 | 658 | -195 | N/A | N/A | N/A |
3/31/2023 | 687 | -145 | -240 | -182 | N/A |
12/31/2022 | 698 | -95 | N/A | N/A | N/A |
9/30/2022 | 633 | -72 | -219 | -104 | N/A |
6/30/2022 | 574 | -103 | N/A | N/A | N/A |
3/31/2022 | 503 | -106 | -472 | -174 | N/A |
3/31/2021 | 257 | -192 | -351 | -247 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: YS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: YS is expected to become profitable in the next 3 years.
Revenue vs Market: YS's revenue (26.9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: YS's revenue (26.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YS's Return on Equity is forecast to be high in 3 years time